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Abstract
30-50% of all lesions amateur and professional sports players will experience during activ-
ity are related to the tendon. Moreover, the incidence of tendinopathy, a precursor to tendon 
rupture, is much higher in both of these groups due to excessive loading of tendons during 
physical activity, insufficient rest afterwards and certain antibiotic use. The tendon anatomical-
ly has both a low blood supply and a low cell turnover rate, which contribute to the relative ease 
by which an athlete can develop tendinopathy. Chronic tendinopathy has very few high-success 
treatments but in recent years, platelet-rich plasma (PRP), a treatment in which platelets are 
isolated from the patient’s blood and injected back into the diseased tendon, has seen promis-
ing results. Prior research has focused on assessing the viability of PRP as a treatment but failed 
to come up with a standard and procedure protocol for its administration. In this study, PRP 
is evaluated in terms of success rate, concentration of cells other than platelets, concentration 
of growth factors, life of growth factors, and size and cross section of the tendon to develop 
a formulation standard, injection plan, and procedure protocol for different tendinopathies. 
Furthermore, a rehabilitation program that takes into account both the treatment and natural 
healing process of the tendon to shorten the time the athlete spends off the field is outlined.
Introduction
Tendinopathy, a precursor to tendon rupture, “is used to describe the clinical picture of 
pain and swelling of a tendon that exhibits no inflammation” (Andia, Sanchez, and Maffulli 
1420). The symptoms of tendinopathy manifest when the rate of healthy tenocyte prolifera-
tion and extracellular matrix (ECM) formation is surpassed by the rate of tissue degeneration. 
Because of its prevalence among athletes and non-athletes alike, tendinopathy is widely studied 
with the leading research focused on cell apoptosis, angiogenesis that has escaped cell control, 
or inflammation and pain, according to Andia, Sanchez, and Maffulli (1420). Despite these 
efforts, not many treatments exist for tendinopathy. 
In recent years, however, a new therapy by the name of platelet-rich plasma (PRP) has 
demonstrated promising results for treating tendinopathy and preventing rerupture in tendons 
after surgical repair. PRP is, in simple terms, a therapy in which platelets are isolated from the 
patient’s blood and injected back into the affected tendon. The platelets release growth factors, 
which can quicken the healing process and promote organized growth of structural proteins 
such as collagen. Prior research has focused on assessing the viability of PRP as a treatment, but 
all have failed to come up with a standardized procedure protocol for its administration. 
In this study, PRP is evaluated in terms of success rate, concentration of platelets, con-
centration of cells other than platelets, life of growth factors, and size and cross section of the 
tendon to develop a formulation standard, injection plan, and procedure protocol for treating 
different tendinous lesions and tendinopathy. Furthermore, a rehabilitation program that takes 
into account both the treatment and natural healing process of the tendon to shorten the time 
the athlete spends off the court or field is outlined.
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Especially in athletes, tendinopathy, if not properly treated, can progress into tendon rup-
ture. Joseph et al. in “Achilles Tendon Biomechanics in Response to Acute Intense Exercise” 
contend that the most common tendon ruptured is the Achilles, attributed to the extreme 
direct and repeated forces and intensive flexing that it experiences during activity, experiencing 
loads up to 12 times the body weight (11). Sports cannot change to utilize the Achilles less, so a 
preventative treatment needs to be employed to protect athletes. According to various studies, 
including those conducted by Rosengarten et al. and Amin et al., normal tendon structure can 
be lost just after 2 days of intense exercise, showing that tendon rupture among athletes is a very 
real risk (Figure 1).
Combined with daily practices and long seasons, transient loss of tendon structure in ath-
letes can cross the point of no homeostatic return according to Dr. Samuel Rosengarten and his 
co-authors in “Australian Football Players’ Achilles Tendons Respond to Game Loads Within 
2 Days: An Ultrasound Tissue Characterization (UTC) Study” (185). Due to the nature of 
sporting, this can lead to permanent damage of the tendon and a decreased sporting ability for 
the athlete. Constant loading and unloading of the tendon makes it more malleable, reducing 
its cross-section. As there is less area for the tendon to absorb impact and more load per square 
inch, the tendon damage is more likely during physical activity. Rosengarten et al., in accor-
dance with Dr. Christophe Charousset et al., assert that the tendon is a connective tissue that 
responds to mechanical loading in the short-term, defined as 24-72 hours, and the long-term, 
defined as 12 weeks-years. Rosengarten et al. also believe that that intense exercise results in 
changes of catabolic and anabolic activity within the tenocytes that tend to normalize after 4 
days or longer and that if enough time is not given in between games and/or practices, these 
microtrauma can transform into disorganization of the collagen and ECM of the tendon (183). 
In all professional sports there is a rigorous practice schedule, and in some, such as baseball and 
basketball, athletes have to play back-to-back games. This does not allow the athlete enough 
time to rest tendons and give them the 4 days required to normalize the structure. 
The tenocyte, the cell tasked with restoring the tendon ECM, is prompted by mechani-
cal stimuli to begin reconstruction. Furthermore, the overloading of the tendon prompts the 
tenocyte to upregulate large proteoglycan expression, leading to an “increase in bound water 
within the ground substance, which may lead to matrix disorganization” (Rosengarten et al. 
186). Thus, the tenocyte will repair the tendon to baseline strength during normal impact and 
use, but hyperloading will disrupt the structure of the tendon and make it much more difficult 
Figure 1. Image of an ultrasound tissue characterization of the Achilles tendon showing structural changes 
due to loading over a period of 4 days. Day 0: Prior to exercise; Days 2 & 4: After exercise. Green regions 
show uniform, intact tendon fibers and blue regions show less uniform, broken/wavy tendon fibers (Rosen-
garten et al. 185).
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for the tenocyte to repair it. Andia, Sanchez, and Maffulli add that the tenocyte responds to 
continual mechanical loading with the release of cytokines IL-1β and tumor necrosis factor-α 
(TNF-α), prostaglandin E2 (PGE2), and neuropeptides P, and connective tissue growth factor 
(CTGF), all of which are pro-inflammatory agents (1422). Fox et al. agree, discussing that ten-
dinopathy is correlated with an increase in inflammatory cytokines TNF-α and IL-1β (2855). 
PRP is usually prepared free with few leukocytes and other inflammatory cells and many its 
growth factors. When injected into the tendon, the growth factors overtake the inflammatory 
cytokines already present in the injured tendon in concentration levels and promote faster heal-
ing.  
Most sports require frequent extension of one or more tendons, leading to tendinopathy 
and in some cases, tendon rupture. Hyperloading of the tendon in a short bout of physical 
activity causes the tendon to experience microtrauma, weakening its overall structure, Amin et 
al. write in “Performance Outcomes after Repair of Complete Achilles Tendon Ruptures in Na-
tional Basketball Association Players” (1868). Charousset et al. concur, finding that tendinopa-
thy is a result of exercise-induced microruptures within the tendon. Professional athletes cannot 
avoid exercise, as it is the nature of their career so a proper preventative treatment needs to be 
developed. Charousset et al. also attribute tendinopathy to “microruptures of the patellar ten-
don, incomplete healing, and extensive neovascularity that may lead to a chronic degenerative 
process” (907). Over time, microruptures can build up and ultimately cause a rupture in one 
or more tendons. If PRP is administered to the tendons that the athlete loads and unloads the 
most, the microruptures within those tendons can be healed faster, which allows the athlete to 
play back-to-back games and conform to intense practice schedules without fear of long-term 
tendon damage. PRP injections at the first signs of tendinopathy can introduce vital healing 
growth factors such as PDGF, which promotes type I collagen growth, and vascular endothelial 
growth factor (VEGF) and platelet derived angiogenesis factor (PDAF), which increase blood 
flow to the inside of the tendon according to the review of research conducted by Andia, San-
chez and Maffulli. Collagen is important to tendon healing and described by Mark D. Rekhter 
as “proteins that consist of a triple helix of polypeptide chains and globular domains,” in his 
article “Collagen Synthesis in Atherosclerosis: Too Much and Not Enough” (376). The tough 
buildup of collagen insures protection from mechanical stress and impact from sports-related 
activities.
Tendinopathy is extremely prevalent in sports as indicated in numbers by Charousset et 
al., which is why a high-success treatment such as PRP needs to be perfected. PRP treatment 
may not only save the careers of athletes in sports with high incidences of tendinopathy, such 
as volleyball and basketball, but also promote more competition by retaining elite athletes for a 
longer period of time. In the study by Amin et al., it is shown that even with PRP treatment, an 
athlete’s game time is reduced after an Achilles tendon rupture, but specific performance factors 
such as rebounds, steals, and blocks normalized when the time played was used as a reference 
frame against the control instead of a per-game reference frame (1865). This data shows that 
although PRP may not allow an athlete to fully regain their stamina, it will enable him or her to 
retain their capabilities as an athlete.
Platelet-Rich Plasma as a Treatment
According to Sánchez et al., tendon healing is a complex process that starts with the secre-
tion of cytokines from broken alpha granules in platelets, which signal cells within the tendi-
nous tissue to proliferate and construct the ECM (246). Despite the many growth factors that 
aid tendon healing, the tendon healing process is a slow one due to its insufficient blood supply 
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and low rates of cell division (Sánchez et al. 245). Blood supply to an injury site is vital as the 
circulatory system is the path through which platelets, growth factors, and other reparative 
molecules are delivered. The healing process of the tendon, according to Sánchez et al. “involves 
several stages, including angiogenesis, cell proliferation, and the deposition of extracellular ma-
trix. These stages are followed by remodeling and maturation, during which the healing tendon 
should ultimately regain its mechanical strength” (245). Andia, Sanchez, and Maffulli disagree 
slightly and propose that the three stages to the healing process of tendons after trauma are, in 
order, “inflammation, angiogenesis, and proliferation” (1418). Although the healing process 
of the tendon is not completely agreed upon, the important fact is that the tendon requires a 
continuous blood supply, growth factors to signal proliferation, and growth factors to signal the 
secretion of a well-structured ECM to heal itself. 
The plethora of growth factors and cytokines secreted by platelets help spur cell growth 
and promote quick repair of the damaged region. Platelets are produced by bone marrow cells 
called megakaryocytes, that make up approximately 1.4 – 4 x 1011 cells/liter of the blood, and 
circulate for approximately 10 days according to Abrams and Dugdale. Platelets are short-lived, 
so once PRP is prepared, it needs to be injected immediately. Andia, Sanchez, and Maffulli fur-
ther discuss that growth factors such as TGF-β, PRGF-BB, and angiopoietin-1 secreted by the 
platelets aid in stabilizing blood vessels, which move along the healing process (1417). Stabiliz-
ing blood vessels is of paramount importance, as unstable blood vessels can do more harm than 
good and cause uncontrolled growth of inflammatory tissue.
The mechanism through which PRP works is simple: it provides an abundance of plate-
lets that can secrete growth factors through alpha granules to synthesize collagen and promote 
organized angiogenesis (Charousset et al. 909, Sánchez et al. 246). PRP exploits the natural 
healing ability of platelets, providing a safe auto-derived treatment with minimal side effects. 
Hom-Lay Wang and Gustavo Avila simply describe PRP as “essentially an increased concentra-
tion of autologous platelets suspended in a small amount of plasma after centrifugation” (192). 
Centrifuging whole bloods draws platelets out of the blood and separates it from other compo-
nents. PRP also includes structural proteins including fibrin, fibronectin, and vitronectin that 
help rebuild the tendon by “facilitat[ing] cell adhesion by forming three-dimensional scaffolds” 
(Andia, Sanchez, and Maffulli 1418). The fibrin matrix aids in building the scaffolding com-
plex, a precursor to tenocyte proliferation (Sanchez et al. 246). If the fibrin matrix is synthesized 
outside of the cell, and injected, there would be a higher concentration of growth factors that 
are able to contribute to the healing process. Also, the fibrin matrix seems to be stimulating the 
growth of collagen I, the most uniform and structurally sound form of collagen, which means a 
faster and better overall recovery. 
PRP is a viable treatment option for tendinopathy and tendon rupture (Figure 2), as it 
introduces platelets to the tendon, which stimulate the production of collagen type I. Sánchez 
et al. also concur adding that PRP contains “TGF-β1, PRGF [PRP], VEGF, epithelial growth 
factor (EGF), hepatocyte growth factor (HGF), and insulin-like growth factor (IGF-I)” (246). 
These molecules produce vital signals that stimulate the synthesis of structural proteins. Fur-
thermore, Andia, Sanchez, and Maffulli reason that the expression of genes IGF-I and TGF- β1 
are important to the healing process of tendons and control the type of collagen being synthe-
sized and that platelets modulate inflammation by controlling a plethora of chemokines that, in 
turn, control the movement of leukocytes and monocytes at the injury site (1418). This creates 
a positive feedback loop in which growth factors flood the cells, drive out inflammatory cyto-
kines (which upregulates growth factors), and so on. 
Healthy vascularization is important in tendons so that growth factors can be circulated 
to the damaged area. Sánchez et al. report that the production of VEGF and HGF in tenocytes 
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helps vascularize the tendon (246). This gives the injured tendon the blood supply that it needs 
to heal quickly. 
Role of Fluoroquinolones in Tendon Rupture
Fox et al. in “Fluoroquinolones Impair Tendon Healing in a Rat Rotator Cuff Repair Mod-
el: A Preliminary Study” assert that there has been a recent trend in fluoroquinolone (FQ)-relat-
ed tendon ruptures. The rate of incidence of FQ-induced tendon rupture is low 0.14-0.4% (it 
is much higher in transplant patients at 12.2-15.6%), Fox et al. claim, but has far-reaching con-
sequences due to FQ’s status as the most prescribed family of antibiotics in the United States 
in 2011 according to Mercola.com (Fox et al. 2852). The side effects of FQ antibiotics may 
be especially stark for the transplant patients because they are already in a weakened state and 
there are few growth factors present in the tendons. Increasing the amount of growth factors in 
circulation may lower the chances for tendon rupture in transplant patients even without PRP 
treatment.
Due to their effectiveness in eliminating both gram-positive and gram-negative bacteria, 
FQs are the best treatment currently for treating tough bacterial infections. Simonin et al. ar-
gue that FQs are not dangerous most of the time to most of the population, generally speak-
ing (869). However, if a professional athlete acquires an infection that requires the use of FQ 
antibiotics, they may experience tendon rupture due to extensive use. Constant loading of the 
tendon after FQ has already mutated tenocytes within it may cause the tendon to overstress and 
rupture. Thus, it is important to administer PRP to high-impact tendons such as the Achilles 
in athletes to help reverse the side effects of FQs and serve as a layer of protection while they are 
taking the antibiotics.
It is not fully known how FQs affect the body, but Simonin et al. suggest FQ antibiotics’ 
high tissue penetration to be a possible reason for inducing tendon rupture (867). This allows 
the antibiotics to cause mutations in tenocytes for a longer period of time. Structural proteins 
are important, as their name implies, in maintaining tendon conformity, but FQs reduce their 
expression in the extracellular matrix, including those of “type I collagen, elastin, fibronectin, 
and b1 integrin” and also “reduced mitochondrial activity, [caused] direct toxicity on collagen, 
elevated levels of activated caspase 3 (an apoptosis marker), and non-cytotoxic inhibition of 
canine tendon cell proliferation” (Fox et al. 2858). Combined with their high tissue penetration 
Figure 2. A) MRI of partial patellar tendon rupture before PRP treatment B) MRI of patellar 
tendon 3 months after 3 PRP injections (Charousset et al. 907) 
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and their ability to induce apoptosis, FQs can wreak havoc inside the tendon and disrupt ten-
don structure.  
In addition to repressing and activating certain genes, FQs cause an influx in reactive ox-
ygen species (ROS) in cells, resulting in a decrease of type I collagen synthesis, according to 
Baboldashti et al. (1935). Baboldashti et al. further explain that the ROS decrease collagen 
synthesis because they activate the transcription factor FOXO1, which is a repressor for type I 
collagen synthesis (1935). Type I collagen is important in maintaining tendon structure and if 
the FQ is targeting it, this can be the cause of tendon rupture in patients treated with FQ. The 
oxidative changes induced by pefloxacin manifested a few days after treatment, supporting the 
findings of other studies. FQ seems to be deeply penetrating tissues and affecting them slowly. 
For example, Simonin et al. add that the ROS modulation of collagen synthesis was seen at least 
5 days after FQ administration (871). In the study conducted by Fox et al., the tendons of the 
test subjects treated with FQs failed structurally. 
Fox et al. discovered that the FQs inflicted microtrauma upon the healing enthesis, weak-
ening the entire tendon (2858). This demonstrates that FQ exposure directly affects the weak-
ening of tendon structure. Less fiber at the healing enthesis not only means compromised struc-
tural integrity but also a lowered ability to heal in the long term. 
Similarly, structurally weak collagen synthesis lowers the ability of the tendon to securely 
bind to the bone (Joseph et al. 1181). With less calcified fibrocartilage to shield the bone, the 
tendon has a higher chance of rupturing. For this reason, the body goes into a “fibroprolifera-
tive response, presumably in an attempt to repair the tendon defect resulting from the depletion 
phase” (Simonin et al. 870). The presence of a natural repair mechanism indicates that the body 
is trying to reverse the adverse effects of the FQ but is not necessarily effective in doing so. As 
shown in the study by Rosengarten et al. and Fox et al., the body may be promoting the growth 
of collagen types that reduce the structural integrity of the tendon. Also, the tendon fibers may 
not be growing uniformly, resulting in disorganization and again, a compromised structure. 
PRP injections can be given at the healing enthesis and spread from there to mitigate the chance 
of rupture. It also means that tendon integrity at the organizational level has been damaged in 
some way to yield these results. 
FQs are known to promote the growth of collagens types II and III, according to Rosen-
garten et al., instead of the ones useful to tendon structure (collagen type I), causing a lapse in 
integrity (185). FQ-related tendinopathy has been correlated with a downregulation of tissue 
inhibitor of metalloproteinase (TIMP-2), an effect known to be associated with tendinopa-
thy, and disorganization of collagen and fibrocartilage (Fox et al. 2855). TIMP is an especially 
important regulatory factor and, if not balanced correctly, can cause tendinopathy and other 
disorders of the tendon. TIMP expression, and thus collagen type II and III synthesis, can be 
reduced with the introduction of inhibitory molecules and flooding the system with collagen 
type I growth factor PDGF (Wang and Avila 192). 
Finally, FQs are linked to gene expression in some way because of their effect on the pro-
duction and inhibition of proteins and molecules. FQs upregulate factors that mark cells for 
apoptosis and prevent expression of those that are important to cellular structure. The ECM is 
extremely important to tendon structure and FQs are altering the concentration of apoptosis 
markers and other chemicals within the matrix. This imbalance is most likely the reason for 
tendon disorganization. 
Application of Platelet-Rich Plasma in Sports 
Andia, Sanchez, and Maffulli draw attention to the prevalence of tendon injuries, stating 
that “an estimated 30-50% of all sports lesions are painful tendon injuries that affect profes-
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sional and recreational athletes in various anatomical locations” (1415). Christophe Charousset 
et al. break this statistic down, claiming that 40% of volleyball and 35% of basketball players 
are affected by tendinopathy (906). Rutland et al. concur, contending that, “overuse tendon 
injuries account for 7% of the injuries seen in United States physician offices and 40% of knee 
injuries in volleyball players” (166). The extremely high number of tendinopathy cases also 
shows a need for an effective preventative treatment to prevent tendon rupture. The rates of ten-
dinopathy and tendon rupture are high, in part, because of the body’s inability to heal tendons 
effectively and because of the few treatment options available. Sánchez et al. in “Comparison of 
Surgically Repaired Achilles Tendon Tears Using Platelet-Rich Fibrin Matrices,” further argue 
that if tendinopathy progresses into tendon rupture, it would be especially devastating because 
the recovery time after operation is lengthy (246). These types of disorders can even drive ath-
letes to abandon their careers and lead painful lives long after their sports careers are over.
Platelet-rich plasma is widely accepted as a treatment and is approved for use in sports. 
The World Anti-Doping Agency states on their website, “despite the presence of some growth 
factors, platelet-derived preparations were removed from the List as current studies on PRP do 
not demonstrate any potential for performance enhancement beyond a potential therapeutic 
effect.” Team physicians are afraid to approve this type of treatment for players, but  science and 
those who have used PRP stand by it. It is so effective that the World Anti-Doping Agency had 
to make it clear that it is not an enhancement. Mikel Sánchez et al. in “Comparison of Surgi-
cally Repaired Achilles Tendon Tears Using Platelet-Rich Fibrin Matrices,” imply an agreement 
with the Agency’s ruling, claiming that PRP is the “safe strategy to accelerate tendon cell pro-
liferation, stimulate the synthesis of type I collagen, and promote neovascularization both in 
vivo and in vitro” (246). PRP is an extremely effective treatment and reduces the time needed 
for an athlete to regain range of motion and to return to sporting (Sánchez et al. 250). Amin et 
al. agree and claim that although “professional athletes have essentially limitless means at their 
disposal to ensure an optimal recovery after an injury… only 60% to 70% can return to their 
sport, usually at a measurably lower level of performance” (1868). PRP is a relatively expensive 
treatment at its current stage, but professional sports teams have a plethora of financial resourc-
es to support the players. Furthermore, the cost of losing a player outweighs the cost of the PRP 
treatment.
Research both in vivo and in vitro has demonstrated the effectiveness of PRP, even if the 
results are not miraculous or a “cure-all” treatment. Especially for an injury such as an Achilles 
tendon rupture, coaches and team physicians should recommend PRP injections concurrent 
with and after surgery, as steroid injections and other treatments have not been very successful 
in the past. 
Andia, Sanchez, and Maffulli claim that studies have indicated that PRP increases the 
blood supply and the amount of circulation-derived cells to the injured tendon (1418). More-
over, Baksh et al. assert in “Platelet-Rich Plasma in Tendon Models: A Systematic Review of 
Basic Science Literature” that most studies indicate higher vascularization of the injured tendon 
and increased tendon strength after PRP treatment. PRP has only shown positive results, min-
imal (if any) side effects, and no deterioration from the initial state. Even if the PRP treatment 
“fails,” the player can take comfort in the fact that they will not experience any rejection of or 
negative reaction to the treatment, as it is derived from their own body.
Charousset et al. claim that 75% of athletes who did not respond to non-operative 
treatments for tendinopathy for at least 4 months in their study were able to return to their 
pre-symptom sporting level after PRP treatment (909). This comes in contrast with operative 
measures, which only allow 50-70% of treated athletes to return to their pre-symptom sporting 
levels (Charousset et al. 909). These are almost indisputable numbers, and team physicians have 
A U C T U S  // VCU’s Journal of Undergraduate Research and Creativity // STEM //  October 2016 8
a responsibility to inform players about PRP therapy because they have a right to know what 
their options are.
In “Performance Outcomes after Repair of Complete Achilles Tendon Ruptures in Na-
tional Basketball Association Players,” Nirav Amin et al. found that after Achilles tendon rup-
tures, not only did the NBA players have reduced performance in those activities that heavily 
relied on the tendon such as rebounds, steals and blocks, but they also had reduced abilities in 
every other component of the game (1869). Amin et al. also found that 36% of NFL players 
who had surgically repaired Achilles tendons and 39% of NBA players (sample size: 18) were 
unable to return to the game (1868). Parekh et al. in “Epidemiology and Outcomes of Achilles 
Tendon Ruptures in the National Football League” similarly found that 36% of NFL players 
who experienced Achilles tendon ruptures did not return to the game and add that those who 
did had over a 50% reduction in performance (285). If PRP is concurrently administered with 
surgical repair of the tendon, and this practice is standardized, then these numbers would be 
much lower. This assertion is corroborated in the study conducted by Sánchez et al., who re-
ported that “two of the amateur athletes in the [PRP] group (soccer and basketball) attained 
preinjury level by 6 months, whereas the 2 remaining athletes (soccer) retired from competitive 
sports for reasons other than the injury; however, their level of activity was high” (249). 
Surgical repair of Achilles tendon ruptures is usually the best option for professional ath-
letes so that they can return to the game, but it is not enough for athletes to stay in the game. 
Andia, Sanchez, and Maffulli report that PRP treatment is also not without risk, as it can de-
crease the cross-sectional area of a tendon after 18 months (1419).
 Dr. Nasim Baboldashti, a researcher at the University of Oxford, and his colleagues 
suggest that PRP can also be used as a “protective strategy at the time of local drug injection to 
prevent some of the adverse side effects of steroids and fluoroquinolones” (1931). Steroids have 
been shown not to be effective treatments against tendinopathy like in the experiment conduct-
ed by Baum et al., but PRP looks hopeful as a preventative treatment for tendon rupture when 
administering fluoroquinolones. 
Recommendations on the Use 
of PRP
There are approximately 
1.4 – 4.0 x 1011 platelets/liter 
of blood, and each platelet has 
a lifespan of ~10 days (Wood-
ell-May et al. 749). According to 
the review conducted by Baksh 
et al., formulations of PRP were 
dependent on the individual 
and varied from 2 – 7 times the 
normal platelet concentration. 
In this study, these concentra-
tions and their effectiveness were 
taken into account and matched 
with types of tendinopathy/ten-
don rupture (used concurrently with surgery; Figure 3).
PRP is not only effective because of the molecules it contains but also because of those 
it does not. Charousset et al. assert that in many studies such as McCarrel and Fortier’s, it 
was “demonstrated that leukocyte concentration is positively correlated with catabolic gene 
Figure 3. Chart detailing suggested concentrations of platelets in PRP 
formulations for recommended protocol in different tendons/tendinop-
athy.
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expression in tendons and ligaments, which suggested that delivery of concentrated leukocytes 
to a site of injury might not provide a favorable environment for tissue healing” (909). Intro-
ducing leukocytes to the tendon during its healing process is not favorable, as the leukocytes 
are attacking the tendon tissues in the absence of pathogens and causing sterile inflammation. 
Creating an environment with minimal leukocytes may promote better and faster healing, as it 
prevents the onset of sterile inflammation. However, it may put the patient at risk for infection 
if they have an already weakened immune system. For this reason, few white blood cells should 
be included in the formulation. Fontenot et al. agree with this assertion to an extent, claiming 
that white blood cells aid in tissue repair by warding off microbes and maintaining an immune 
system presence in the injured area (1270). 
Commercial preparation of PRP is very efficient and the best option in the long-term. 
Although the upfront cost is significantly greater than other methods, the efficiency, reduc-
tion in chance for human error, and simple processing of whole blood make it suitable for a 
clinical setting. Charousset et al. used the Arthrex ACP system to isolate platelet-rich plasma 
from whole blood. The ACP contained more than two times the density of platelets than whole 
blood (907). The preparation process is simple according to Charousset et al. who drew 15 mL 
of venous blood “into the Arthrex Double Syringe System (Arthrex Inc.) and then centrifuged 
at 1700 rpm for 5 minutes. A final volume of 6 mL of pure PRP was obtained” (907).
The most effective concentration of platelets in the PRP in relation to whole blood is 
debated and varies from 2-10 times. However, as Fontenot et al. point out, “some studies sug-
gest that high platelet numbers are no better than moderate numbers or may actually have 
detrimental effects” (1267). It is better to be on the safe side and inject a lower concentration 
of platelets and then administer more injections than to do the opposite. After reviewing the 
literature and comparing different tendon densities, tensile strengths, and size, a guide to con-
centration levels was developed (Figure 3). 
PRP can be harmful or useless without the correct formulation, so balancing how much 
PRP injected is of paramount importance. The current protocol devised by Dr. Peter Weh-
ling, according to the Chicago Tribune, is to extract PRP serum from ~60mL of blood to and 
inject it into the patient’s tendons six times over the treatment course. This treatment can be 
used as a guide but needs to be tailored according to tendon density and size to be most effec-
tive. A blanket treatment may even do more harm than good if too much tissue is regenerated 
according to the mechanism described by Wang and Avila in “Platelet Rich Plasma: Myth or 
Reality?” Andia, Sanchez, and Maffulli suggest that injecting patients weekly with PRP over 2-3 
weeks using ultrasonography as a guidance tool is an effective way to administer the treatment 
(1420). Charousset et al. agree with this procedure protocol, adding that a 16-MHz probe gave 
a clear image of the internals and that a 22-gauge needle was used to inject the PRP “within 
and around the hypoechoic area” (907). Ultrasound imaging is optional but is recommended 
as it allows the physician to accurately guide the injection. This allows for a more effective treat-
ment and fewer injections over the course of the treatment. Charousset et al. add “75% [of the 
treated patients] were able to return to their presymptom sporting level … after a mean period 
of 3 months, and this sporting level was maintained until the 2-year follow-up” (909). The 
3-month MRI in 57% of patients confirmed a complete repair of the tendon. This conservative 
procedure is an alternative treatment to surgery, which has allowed only 50% to 70% of the 
treated patients (either arthroscopic or open surgery) to return to a presymptom sporting level” 
(Charousset et al. 909). 
Even though the Arthrex Inc. preparation system mentioned previously yields high-grade 
PRP, the delivery method needs to be refined. PRP needs to be injected in and around the ten-
don uniformly, presenting a challenge as one cannot just move up the tendon, injecting PRP at 
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regular intervals on the skin. A possible solution is using the same technique used for lubricat-
ing joints with Orthovisc (high molecular weight hyaluronan) fluid—moving the needle while 
it is inside the patient. This may cause the hypodermic needle to stretch the entrance hole, but 
this is better than creating multiple injection sites. 
PRP alone cannot miraculously cure tendinopathy and fix tendon rupture, but instead, it 
has to be combined with a variety of other treatments to be most effective. One of these is phys-
ical therapy (PT). Stanish, Rubinovich, and Curwin suggest that the PT program consists of 
stretching, progressive loading, and increase in the speed of exercise (66). The stretching helps 
with stratifying the tendon and pain from joint movement. The load on the tendon should be 
increased weekly and lessened if the patient experiences pain. Speeding up the contractions 
allows the tendon to take on more force according to Stanish, Rubinovich, and Curwin (66). 
The exercise program should last for at least 4 weeks but 6 weeks is recommended to ensure 
complete healing and to minimize the risk of rerupture. Charousset et al. suggest that running 
should be taken up after 6 weeks and sporting after 8 weeks (908). 
Many studies lay claim to the ineffectiveness and potential harmful effects of PRP, yet they 
fail to provide concrete data to corroborate these assertions. Studies have also erred on the side 
of caution, arguing that more research is needed before PRP can be administered to patients, 
as it may present extremely negative side effects in the long term. Although these claims might 
be well warranted under normal circumstances in testing of synthetic drugs, PRP is derived 
from the patients’ bodies and unused portions of it is metabolized soon after it is administered. 
For this reason, any side effects will manifest in the short term, and no significant ones have 
been documented. Of course, administering too much of any substance that interferes with 
cell signaling can be harmful in large quantities, which is why in this study, the formulation 
standard lies more on the conservative side. Athletes should not be over-vigilant when it comes 
to making the decision of whether to try PRP or not. If alternate treatments continue to fail, 
they should consider PRP as a serious option, as it has displayed extremely positive results in the 
past. In the case that the treatment is successful, athletes will not only enjoy the benefit of a fast 
and more complete recovery from tendon rupture and tendinopathy but will also be providing 
more data on which scientists can rely and perfect PRP technology for widespread use. 
PRP is a promising treatment for alleviating tendinopathy and preventing tendon re-rup-
ture postoperatively. Although the treatment has been developed extensively in the past few 
years, a standard for its administration has not been set. Gathering recommendations from 
previous studies and taking into account the different tendons of the body, a comprehensive 
protocol was developed in this study (Table 1). Figure 3 and Table 1 should serve as a guide 
for administering PRP to athletes after tendinopathy or rupture in the tendons outlined. Ulti-
mately, however, the provider must make the final decision on the formulation, the injection 
volume, and the exercise program until there is more research on the administration of PRP.
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Table 1. Procedure for Administering Platelet-Rich Plasma
1 Establish a baseline platelet count
2 Draw 15 mL of whole blood
3 Centrifuge at speed recommended by the Arthrex ACP Double Syringe System for 5 
minutes
4 Isolate platelets and check concentration, matching it to Figure 3; do not exceed an 
injection volume of 2.5 mL
5 Inject PRP in and around the tendinous lesion (optional: use ultrasonography to guide 
the injection)
6 Repeat procedure once a week after the first injection for 2 more weeks, for a total of 3 
injections
7 Enroll patient in a therapy program focused on stretching, light extensions of the ten-
don, and mild exercise; increase difficulty on a weekly basis
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